doxapram has been researched along with Bronchopulmonary Dysplasia in 3 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Bronchopulmonary Dysplasia: A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)." | 7.83 | Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016) |
| "Doxapram has been advocated as a treatment for persistent apnea of prematurity (AOP)." | 3.83 | Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity. ( Brouwer, E; Onland, W; Rijken, M; Te Pas, AB; Ten Hove, CH; van Kaam, AH; van Wassenaer-Leemhuis, AG; Vliegenthart, RJ, 2016) |
| "Doxapram has the potential to improve neonatal outcomes by improving respiration, but the safety concerns need to be weighed against the potential risks of invasive mechanical ventilation." | 3.30 | Doxapram versus placebo in preterm newborns: a study protocol for an international double blinded multicentre randomized controlled trial (DOXA-trial). ( Allegaert, K; Carkeek, K; Cassart, V; Cornette, L; de Boode, WP; de Kort, EHM; Dijk, PH; Flint, RB; Hemels, MAC; Hermans, I; Hutten, GJ; Hütten, MC; Kelen, D; Kroon, AA; Lacaze-Masmonteil, T; Lefevere, J; Nuytemans, DH; Onland, W; Pas, ABT; Plaskie, K; Poley, MJ; Poppe, JA; Reiss, IKM; Simons, SHP; Smits, A; Stewart, B; Storm, KK; van Kaam, AH; van Weissenbruch, MM; Voeten, M; Willemsen, SP; Williams, O; Zonnenberg, IA, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Poppe, JA | 1 |
| Flint, RB | 1 |
| Smits, A | 1 |
| Willemsen, SP | 1 |
| Storm, KK | 1 |
| Nuytemans, DH | 1 |
| Onland, W | 2 |
| Poley, MJ | 1 |
| de Boode, WP | 1 |
| Carkeek, K | 1 |
| Cassart, V | 1 |
| Cornette, L | 1 |
| Dijk, PH | 1 |
| Hemels, MAC | 1 |
| Hermans, I | 1 |
| Hütten, MC | 1 |
| Kelen, D | 1 |
| de Kort, EHM | 1 |
| Kroon, AA | 1 |
| Lefevere, J | 1 |
| Plaskie, K | 1 |
| Stewart, B | 1 |
| Voeten, M | 1 |
| van Weissenbruch, MM | 1 |
| Williams, O | 1 |
| Zonnenberg, IA | 1 |
| Lacaze-Masmonteil, T | 1 |
| Pas, ABT | 1 |
| Reiss, IKM | 1 |
| van Kaam, AH | 2 |
| Allegaert, K | 1 |
| Hutten, GJ | 1 |
| Simons, SHP | 1 |
| Ten Hove, CH | 1 |
| Vliegenthart, RJ | 1 |
| Te Pas, AB | 1 |
| Brouwer, E | 1 |
| Rijken, M | 1 |
| van Wassenaer-Leemhuis, AG | 1 |
| Greenough, A | 1 |
| Prendergast, M | 1 |
1 review available for doxapram and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Difficult extubation in low birthweight infants.
Topics: Adrenal Cortex Hormones; Bronchopulmonary Dysplasia; Decision Making; Dexamethasone; Doxapram; Gluco | 2008 |
1 trial available for doxapram and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Doxapram versus placebo in preterm newborns: a study protocol for an international double blinded multicentre randomized controlled trial (DOXA-trial).
Topics: Bronchopulmonary Dysplasia; Caffeine; Double-Blind Method; Doxapram; Gestational Age; Humans; Infant | 2023 |
1 other study available for doxapram and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Long-Term Neurodevelopmental Outcome after Doxapram for Apnea of Prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Central Nervous System Stimulants; Child Development; Doxapram; D | 2016 |